Table 1 Baseline clinical and angiographic characteristics
| Â | CON | Group A | Group B | Group C | p value |
|---|---|---|---|---|---|
(n = 25) | (n = 27) | (n = 26) | (n = 26) | ||
Age, years | 58.8 ± 8.4 | 60.0 ± 7.0 | 58.3 ± 9.8 | 57.3 ± 10.5 | 0.747 |
Female, % | 12 | 7 | 12 | 8 | 0.915 |
Hypertension, % | 48 | 59 | 50 | 73 | 0.490 |
Hyperlipidemia, % | 48 | 26 | 65 | 42 | 0.281 |
Diabetes, % | 32 | 31 | 15 | 15 | 0.544 |
Previous angina, % | 24 | 30 | 23 | 31 | 0.901 |
Smoking (current or former), % | 40 | 54 | 62 | 31 | 0.130 |
Family history for CAD, % | 28 | 26 | 54 | 46 | 0.128 |
CAD (1-/2-/3-vessel disease), n | 19/5/1 | 22/3/2 | 19/4/3 | 17/8/1 | 0.810 |
Infarct territory (anterior/inferior), % | 85/15 | 70/30 | 69/27 | 73/23 | 0.564 |
Infarct-related vessel (LAD/RCA/LCX), % | 80/16/4 | 82/11/7 | 73/23/4 | 73/19/8 | 0.911 |
Previous interventional therapy, n | 3 | 5 | 2 | 4 | 0.638 |
PCI for additional stenosis in non-infarct-related vessels, n | 3 | 4 | 3 | 4 | 0.970 |
Time to reperfusion/stent, hours | 7.0 ± 2.1 | 7.0 ± 2.2 | 5.9 ± 3.5 | 6.6 ± 3.2 | 0.766 |
TIMI flow grade before PCI | 0.32 ± 0.69 | 0.37 ± 0.69 | 0.31 ± 0.74 | 0.38 ± 0.80 | 0.977 |
Thrombolysis before PCI, n | 5 | 4 | 3 | 7 | 0.702 |
Drug eluting stent/bare stent/no stent, n | 10/15/0 | 19/8/0 | 10/14/2 | 10/14/2 | 0.766 |
GPIIb/IIIa inhibitor during acute PCI, % | 20 | 15 | 12 | 15 | 0.876 |
Intravenous catecholamine, n | 2 | 2 | 1 | 1 | 0.875 |
CPR during AMI, n | 2 | 1 | 0 | 2 | 0.501 |
Creatine kinase MB max, U/L | 158.6 ± 98.5 | 169.2 ± 102.0 | 153.8 ± 74.3 | 160.1 ± 88.1 | 0.940 |
Troponin T max, ng/mL | 11.0 ± 10.3 | 10.0 ± 7.5 | 9.3 ± 9.0 | 8.9 ± 6.7 | 0.818 |
CRP max, mg/dl | 12.3 ± 12.2 | 13.8 ± 12.4 | 12.3 ± 11.4 | 11.6 ± 7.5 | 0.901 |
White blood cells, ×109/L | 9.3 ± 1.7 | 9.4 ± 2.7 | 9.4 ± 2.0 | 9.5 ± 2.3 | 0.990 |
Time from stent to cell therapy, hours | – | 1.6 ± 0.9 h | 4.7 ± 1.3 d | 11.1 ± 3.3d | – |
TIMI flow grade before study therapy | 2.76 ± 0.44 | 2.89 ± 0.32 | 2.73 ± 0.45 | 2.81 ± 0.40 | 0.513 |
TIMI flow grade after study therapy | 2.88 ± 0.33 | 2.93 ± 0.37 | 2.80 ± 0.40 | 2.88 ± 0.33 | 0.637 |
Number of BMC injected, ×108 | – | 4.8 ± 2.5 | 5.0 ± 3.8 | 4.8 ± 1.8 | – |
CD34+, ×106 | – | 1.8 ± 1.0 | 1.2 ± 0.8 | 0.9 ± 0.6 | – |
CD133+, ×105 | – | 4.1 ± 2.7 | 3.0 ± 2.0 | 2.3 ± 2.1 | – |
Baseline ejection fraction (echocardiography), % | 43.5 ± 3.5 | 44.7 ± 3.9 | 43.1 ± 6.0 | 43.1 ± 6.4 | 0.603 |
End-diastolic volume, ml | 157.7 ± 26.1 | 153.1 ± 27.9 | 151.7 ± 21.8 | 154.5 ± 26.7 | 0.639 |
End-systolic volume, ml | 93.9 ± 17.3 | 90.8 ± 19.3 | 90.5 ± 18.3 | 97.0 ± 25.1 | 0.523 |
Medication at discharge | |||||
 Aspirin (%) | 100 | 96.1 | 100 | 100 | 0.420 |
 Clopidogrel (%) | 96.0 | 100 | 100 | 100 | 0.372 |
 ACE inhibitor or ATII blocker, % | 100 | 100 | 96.2 | 100 | 0.396 |
 Beta-blocker, % | 92.0 | 100 | 100 | 96.1 | 0.558 |
 Statin, % | 100 | 100 | 100 | 100 | 1.000 |
 Medication at 12 months | |||||
 Aspirin, % | 96.0 | 96.2 | 100 | 100 | 0.573 |
 Clopidogrel, % | 88.0 | 77.8 | 80.8 | 88.5 | 0.435 |
 ACE inhibitor or ATII blocker, % | 96.0 | 92.6 | 92.0 | 96.1 | 0.894 |
 Beta-blocker, % | 96.0 | 92.3 | 100 | 96.1 | 0.589 |
 Statin, % | 96.0 | 92.3 | 96.1 | 96.1 | 0.914 |